Examkin

Question

Difficulty: HardPsychopharmacology and Psychological Therapies

A 34-year-old female with schizoaffective disorder is admitted to the hospital for intravenous antibiotic therapy for a complicated cellulitis. Her psychiatric symptoms have been well controlled for the past three years on a stable dose of clozapine. She typically smokes one and a half packs of cigarettes daily but is currently in a strict smoke-free inpatient unit; a transdermal nicotine patch was prescribed on admission to prevent withdrawal. Her other home medications include a combined oral contraceptive pill and ibuprofen as needed. On hospital day 4, the patient becomes progressively lethargic and develops significant sialorrhea. Later that evening, she experiences a generalized tonic-clonic seizure. Her vital signs are temperature 37.1°C (98.8°F), blood pressure 110/70 mm Hg, pulse 92/min, and respirations 14/min. Laboratory studies show a normal basic metabolic panel, and her white blood cell count is 8,500/mm³. Which of the following is the most likely pharmacological explanation for this patient's acute neurological presentation?

  1. A
    Competitive inhibition of cytochrome P450 enzymes by the newly prescribed transdermal nicotine
  2. B
    Progression of drug-induced bone marrow suppression leading to a secondary central nervous system infection
  3. Decreased hepatic drug clearance due to the removal of a cytochrome P450 inducerAnswer
  4. D
    Synergistic lowering of the seizure threshold by the newly initiated antibiotic therapy
  5. E
    Pharmacodynamic interaction resulting in acute central nervous system dopaminergic hypersensitivity

Answer

The correct underlying mechanism is decreased hepatic drug clearance due to the removal of a cytochrome P450 inducer.
The correct answer describes decreased hepatic drug clearance due to the removal of a cytochrome P450 inducer. This patient is exhibiting textbook signs of clozapine toxicity, which classically presents with severe sedation (lethargy), sialorrhea (excessive drooling), and dose-dependent generalized tonic-clonic seizures. Clozapine is primarily metabolized by the cytochrome P450 1A2 (CYP1A2) hepatic enzyme. Tobacco smoke contains polycyclic aromatic hydrocarbons (PAHs), which are potent inducers of CYP1A2. When a heavy smoker is abruptly placed in a smoke-free environment (such as an inpatient hospital admission), the induction of CYP1A2 rapidly diminishes. This leads to a significant decrease in the clearance of clozapine, causing serum levels to rise precipitously into toxic ranges, even though the prescribed medication dose remained unchanged.

Step-by-Step Solution

1
Analyze the patient's acute symptoms.
The patient exhibits lethargy, sialorrhea (excessive drooling), and a generalized tonic-clonic seizure.
Identifying the clinical toxidrome is the first step to pinpointing the offending agent.
2
Correlate the toxidrome with the patient's medication list.
The symptoms represent classic dose-dependent toxicities of clozapine.
Clozapine side effects include severe sedation, prominent sialorrhea, and a dose-dependent reduction in the seizure threshold.
3
Identify the trigger for the sudden onset of toxicity in a previously stable patient.
The patient is a heavy smoker who was abruptly forced to cease smoking upon hospital admission.
Changes in environmental exposures, particularly smoking, can drastically alter the metabolism of psychiatric medications.
4
Determine the pharmacokinetic mechanism connecting smoking cessation to clozapine levels.
Tobacco smoke contains polycyclic aromatic hydrocarbons (PAHs) that strongly induce CYP1A2, the primary enzyme that metabolizes clozapine.
Abrupt smoking cessation leads to a rapid loss of CYP1A2 induction, causing clozapine metabolism to slow down and serum levels to spike, precipitating toxicity despite an unchanged oral dose.

Key Concept

Polycyclic aromatic hydrocarbons in tobacco smoke strongly induce CYP1A2. Abrupt smoking cessation in patients taking CYP1A2 substrates like clozapine leads to decreased clearance, elevated serum levels, and potentially life-threatening dose-dependent toxicity.
Rate this question

Topics

Psychopharmacology and Psychological Therapies

More questions from this topic